Studies have shown that antibodies blocking IL-12 and IL-23 are effective in the treatment of IBD (113), but blocking IL-17A in CD has been found to be ineffective and has a higher incidence of adverse events. The gene discussed is IL17A; the disease is inflammatory bowel disease.